A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

Launched by FEDERATION FRANCOPHONE DE CANCEROLOGIE DIGESTIVE · Aug 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying rare types of primary liver cancers, including conditions like hepatocholangiocarcinoma and fibrolamellar carcinoma. The goal is to gather information about the features of these cancers, including how they look under a microscope and on scans, and to collect blood and tumor samples. This information will help researchers understand the effectiveness of different treatments and find better ways to diagnose and evaluate these cancers in the future.

To be eligible for this study, participants must be 18 years or older and have a confirmed diagnosis of one of the specified liver cancers after January 1, 2018. Living patients who wish to participate need to agree to the research and sign a consent form. Those who take part can expect to contribute to important research that may lead to new insights and treatments for these rare cancers. The study is currently recruiting participants, and it is open to all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years of age or older,
• • with histologically proven hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma or hepatic angiosarcoma
• • diagnosed after January 01, 2018 living or deceased at the time of registration in the cohort
• • for living patients who have not objected to the research: (note of non-objection to be attached° agreeing to participate in ancillary studies must sign the biological consent form for participation in biological studies.
• Exclusion Criteria:
• • without social security
• • No access to tumor block